It might take a while for this AI company to prove its worth, if it ever does so.

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

The company published its latest quarterly earnings report this morning. It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a ...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals stock soared as much as 121% on Wednesday after it received an investment from Nvidia. Nvidia said it would invest $50 million in the company as it works to use AI for drug ...